ES2018387A6 - Procedimiento de obtencion de un medicamento para inhibir la infeccion de celulas por virus hiv. - Google Patents

Procedimiento de obtencion de un medicamento para inhibir la infeccion de celulas por virus hiv.

Info

Publication number
ES2018387A6
ES2018387A6 ES8902912A ES8902912A ES2018387A6 ES 2018387 A6 ES2018387 A6 ES 2018387A6 ES 8902912 A ES8902912 A ES 8902912A ES 8902912 A ES8902912 A ES 8902912A ES 2018387 A6 ES2018387 A6 ES 2018387A6
Authority
ES
Spain
Prior art keywords
monoclonal antibody
viruses
inhibiting cell
cell infection
infection
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES8902912A
Other languages
English (en)
Inventor
Dr Frank Emmrich
Dr Gerhard Hunsmann
Dr Wolfgang Luke
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Deutsches Primatenzentrum GmbH
Max Planck Gesellschaft zur Foerderung der Wissenschaften eV
Original Assignee
Deutsches Primatenzentrum GmbH
Max Planck Gesellschaft zur Foerderung der Wissenschaften eV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Deutsches Primatenzentrum GmbH, Max Planck Gesellschaft zur Foerderung der Wissenschaften eV filed Critical Deutsches Primatenzentrum GmbH
Publication of ES2018387A6 publication Critical patent/ES2018387A6/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2812—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1036—Retroviridae, e.g. leukemia viruses
    • C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
    • C07K16/1063—Lentiviridae, e.g. HIV, FIV, SIV env, e.g. gp41, gp110/120, gp160, V3, PND, CD4 binding site
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • AIDS & HIV (AREA)
  • Public Health (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

PROCEDIMIENTO DE OBTENCION DE UN MEDICAMENTO PARA INHIBIR LA INFECCION DE CELULAS POR VIRUS HIV. PROCEDIMIENTO PARA PREPARAR UN MEDICAMENTO DESTINADO A PREVENIR UNA INFECCION POR HIV Y SIV Y/O LA PROPAGACION DE LOS VIRUS EN EL CUERPO DESPUES DE HABERSE PRODUCIDO LA INFECCION, CARACTERIZADO PORQUE COMPRENDE LAS OPERACIONES DE A) CULTIVAR LINEAS DE CELULAS DE HIBRIDOMA ECACC 88050502, B) SEPARAR LOS ANTICUERPOS MONOCLONADOS 30F16H5 PRODUCIDOS DEL MEDIO DE CULTIVO, Y C) INCORPORAR LOS ANTICUERPOS SEPARADOS EN MATERIALES FISIOLOGICAMENTE ACEPTABLES, EVENTUALMENTE JUNTO CON OTROS MATERIALES DE VEHICULO Y ADITIVOS USUALES, PARA OBTENER UNA FORMA DE ADMINISTRACION DE DICHOS ANTICUERPOS FARMACEUTICAMENTE APROPIADA.
ES8902912A 1988-08-23 1989-08-23 Procedimiento de obtencion de un medicamento para inhibir la infeccion de celulas por virus hiv. Expired - Lifetime ES2018387A6 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE3828582A DE3828582A1 (de) 1988-08-23 1988-08-23 Monoklonaler antikoerper zur inhibierung der infektion von zellen durch hiv-viren

Publications (1)

Publication Number Publication Date
ES2018387A6 true ES2018387A6 (es) 1991-04-01

Family

ID=6361424

Family Applications (1)

Application Number Title Priority Date Filing Date
ES8902912A Expired - Lifetime ES2018387A6 (es) 1988-08-23 1989-08-23 Procedimiento de obtencion de un medicamento para inhibir la infeccion de celulas por virus hiv.

Country Status (7)

Country Link
EP (1) EP0430999A1 (es)
JP (1) JPH04501055A (es)
AU (1) AU629847B2 (es)
DE (1) DE3828582A1 (es)
DK (1) DK24891D0 (es)
ES (1) ES2018387A6 (es)
WO (1) WO1990002199A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3919294C2 (de) * 1989-06-13 1998-04-23 Frank Prof Dr Emmrich Verwendung eines monoklonalen Antikörpers zur Behandlung einer Autoimmunerkrankung
US5961976A (en) * 1996-06-03 1999-10-05 United Biomedical, Inc. Antibodies against a host cell antigen complex for pre- and post-exposure protection from infection by HIV
EP2471543A1 (en) * 2010-12-02 2012-07-04 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Tolerance induction or immunosupression to prevent in particular Graft-versus-Host-Disease (GvHD) by short-term pre-incubation of transplanted cell suspensions, tissues or organs coated with ligands to cell surface molecules
US11180555B2 (en) 2014-09-16 2021-11-23 Ubi Us Holdings, Llc. Antibodies directed against CD4 for the treatment and functional cure of HIV
EP3497133A4 (en) 2016-08-13 2020-03-25 UBI IP Holdings TREATMENT AND DELAYED VIROLOGICAL REMISSION OF HIV INFECTIONS BY ANTIBODIES AGAINST CD4 IN HAIR-STABILIZED PATIENTS

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683295A (en) * 1984-05-24 1987-07-28 Scripps Clinic And Research Foundation Method for the preparation of anti-receptor antibodies
FR2570278B1 (fr) * 1984-09-14 1987-02-13 Pasteur Institut Compositions et procede pour proteger les lymphocytes t contre l'agent etiologique des lymphadenopathies et du syndrome d'immunodepression acquise
EP0280710B1 (en) * 1986-08-21 1996-03-20 The Trustees Of Columbia University In The City Of New York Dna encoding the t cell surface protein t4 and use of fragments of t4 in the treatment of aids
FI891226A (fi) * 1988-04-28 1989-10-29 Univ Leland Stanford Junior Reseptordeterminanter i anti-t-celler foer behandling av autoimmunsjukdom.
DE69020914T2 (de) * 1989-01-23 1996-03-07 Abbott Lab Monoklonale Antikörper von Ratten gegen menschliche Antigene und Verfahren zu deren Herstellung.

Also Published As

Publication number Publication date
EP0430999A1 (de) 1991-06-12
DK24891A (da) 1991-02-13
JPH04501055A (ja) 1992-02-27
WO1990002199A1 (de) 1990-03-08
DK24891D0 (da) 1991-02-13
DE3828582A1 (de) 1990-03-01
AU4070289A (en) 1990-03-23
AU629847B2 (en) 1992-10-15

Similar Documents

Publication Publication Date Title
ES8606289A1 (es) Un procedimiento para la preparacion de piridazinaminas.
AU549204B2 (en) Intravenously injectable immune serum globulin
ES2156852T3 (es) Citoquina mamifera, il-11.
UA26303A1 (uk) Фармацевтичhа композиція, яка має імуhосупресорhу та аhтимікробhу активhість
MY110217A (en) Use of l-deprenyl for retarding deterioration due to aging in dogs
EP0230574A3 (en) Pharmaceutical compositions against infections caused by lav/htlv iii virus and the use thereof
OA06920A (fr) Halogénures d'ammonium spiro-quartenaire, leur procédé de préparation et leur utilisation dans un procédé de production de N-(2-pyrimidinyl) pipérazinyl-alkylazospiro-alcanédiones.
DE58909850D1 (de) Arzneimittel zur behandlung von krebs, aids und viruserkrankungen
ATE70453T1 (de) Verwendung von interleukin-1-proteinen gegen arthritis.
ES2018387A6 (es) Procedimiento de obtencion de un medicamento para inhibir la infeccion de celulas por virus hiv.
ES458710A1 (es) Un metodo para la obtencion de un preparado de cefalexina deaccion prolongada.
ES8107192A1 (es) Un procedimiento para la preparacion de un compuesto sele- ccionado entre el grupo formado por una imidazolilurea
EP0339163A3 (en) Monoclonal antibodies specific for hiv and hybridomas for their production
ES8100800A1 (es) Procedimiento para la preparacion de derivados furanonicos
DE3585049D1 (de) Monoklonale antikoerper.
ATE15762T1 (de) Pharmazeutische zusammensetzungen mit gehalt an 7,8-dihydroxy-1-(hydroxy-phenyl)-2,3,4,5tetrahydro-1h-3-benzazepin-derivaten und an einem beta-adrenergischen blocker.
GB1483650A (en) Pharmaceutical preparations based on mesterolone
IT8121647A0 (it) Bomboletta a pressione con contenitore per componente separato da aggiungere al momento dell'uso.
GB1051686A (es)
DK499583D0 (da) Fremgangsmade til fremstilling af en isoquinolinforbindelse
ATE26214T1 (de) Pharmazeutische zusammensetzungen.
ES8800119A1 (es) Un procedimiento para la preparacion de un producto activador de suelos a base de una biomasa del micelio de hongo proveniente de la produccion de penicilina.
SE7514774L (sv) Accelerator for fri-radikal katalyserad polymerisation.
ES8303297A1 (es) Un procedimiento para la preparacion de un nuevo reptido activo.
IE36780B1 (en) New pharmaceutical preparations